Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea

Hyeon Woo Jeon; Sook Jung Yun; Seung-Chul Lee; Young Ho Won; Jee-Bum Lee

doi:10.5021/ad.2018.30.1.13

Journal List > Ann Dermatol > v.30(1) > 1095375

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jeon, Yun, Lee, Won, and Lee: Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea

Original Article

Annals of Dermatology 2018; 30(1): 13-19.

Published online: 26 December 2017

DOI: https://doi.org/10.5021/ad.2018.30.1.13

Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea

Hyeon Woo Jeon, Sook Jung Yun, Seung-Chul Lee, Young Ho Won, Jee-Bum Lee

Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea.

Corresponding author: Jee-Bum Lee, Department of Dermatology, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Korea. Tel: 82-62-220-6684, Fax: 82-62-222-4058, jbmlee@jnu.ac.kr

Received 24 March 2017 Revised 18 April 2017 Accepted 2 May 2017

The Korean Dermatological Association and The Korean Society for Investigative Dermatology

(open-access, http://creativecommons.org/licenses/by-nc/4.0):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Bullous pemphigoid (BP) is a common autoimmune-mediated blistering skin disease that is significantly associated with mortality and morbidity. However, few studies regarding the mortality and comorbidity profiles of BP have been reported in Korea.

Objective

To evaluate and compare the mortality, comorbidity profiles, and risk factors between patients with BP who visited our clinic and an age-matched general population of Korea.

Methods

We retrospectively evaluated 103 patients diagnosed with BP between 2006 and 2013 at Chonnam National University Hospital in Gwangju, Korea.

Results

The 1-year, 2-year, and 5-year mortality rates of the patients were 18.44%, 28.16%, and 42.00%, respectively. The median age was 76 years (range, 41~96 years). The standardized mortality ratio of patients with BP was 1.83 times that of the age- and sex-matched general population of Korea. Old age at the time of diagnosis, cardiac disease and renal disease were associated with increased 5-year mortality. In addition, the prevalence of diabetes, stroke, dementia, and Parkinson's disease was higher among BP patients than in the general population.

Conclusion

The mortality rate of patients with BP is higher than that of the general Korean population. Korean patients with BP are more likely to have dementia, Parkinson's disease, diabetes, and stroke. Risk factors for increased 5-year mortality include old age at the time of diagnosis and medical comorbidities, especially cardiac disease and renal disease.

Go to :

Keywords: Bullous pemphigoid, Comorbidity, Mortality, Risk factors

INTRODUCTION

Bullous pemphigoid (BP) is the most common subepidermal blistering disease, characterized by blisters mainly on the skin in the elderly1. The clinical features of BP include pruritic generalized tense bullae and urticarial plaques2. BP has been reported to be significantly associated with mortality; the first-year mortality rate varies between 6% and 44%, depending on the country, while the 1-year standardized mortality ratio (SMR) ranges from 2 to 153 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31. The reason for this large difference in mortality rates among countries is unclear.

BP has also been associated with several comorbidities. It is associated with an autoantibody response to BP180 (BPAg2) and BP230 (BPAg1), two components of adhesion complexes promoting dermo-epidermal cohesion. BPAG1, encoded by DST, has specific isoforms: BPAG1-e is mainly expressed in epithelial tissue, anchoring keratin-containing intermediate filaments to hemidesmosomes, while BPAG1-a and BPAG1-b are expressed in neural and muscle tissues32 33 34. Although the pathogenesis of BP remains unknown, previous studies suggest that the cross-reactivity between these isoforms could be pathogenic in BP34. Furthermore, recent studies have shown that patients with BP are more likely to have neurological and psychiatric diseases than general population35 36 37 38 39.

Nevertheless, only few studies regarding the mortality, prognostic factors, and comorbidity profiles of BP have been reported in Korea. The main objective of this study was to evaluate the mortality, comorbidity profiles, and risk factors of patients with BP who visited our clinic, compared to those of an age-matched general population of Korea.

Go to :

MATERIALS AND METHODS

Study population

We retrospectively evaluated patients who were diagnosed with BP at Chonnam National University Hospital (CNUH) in Gwangju, Korea, between 2006 and 2013. The diagnosis of BP was based on the following criteria: (1) consistent clinical features, (2) histopathological evidence of subepidermal blister formation, (3) deposits of immunoglobulin G (IgG) and/or C3 along the basement membrane zone, as assessed by direct immunofluorescence (IF) microscopy, (4) presence of circulating autoantibodies bound to the epidermal side of salt-split skin, detected by indirect IF studies, and (5) presence of IgG autoantibodies against BP180 and BP230 antigens, detected by enzyme-linked immunosorbent assay or Western blot analysis. The diagnosis was based on the presence of the clinical (1), histological (2) and immunological (3) criteria, and at least 1 of the serological (4 and 5) criteria. In total, 103 patients with BP who satisfied the diagnostic criteria were enrolled in this study. After an initial workup, patients are usually treated with corticosteroids with or without corticosteroid-sparing agents, such as dapsone, tetracycline, azathioprine, and mycophenolate mofetil. Patients who are refractory to corticosteroid therapy were treated with intravenous immunoglobulin. The demographic data collected include sex, age at the time of diagnosis, date of death, treatment modalities, and comorbidities. Patients lost to follow-up were contacted via the telephone to determine whether they were alive or dead, and in the case of the latter, the date of death.

For statistical analysis, comorbidities were grouped as follows: cardiac disease (e.g., coronary artery disease, cardiac arrhythmia, and congestive heart failure), hypertension, diabetes mellitus, dementia, stroke, other neurological diseases (e.g., Parkinson's disease, psychosis, epilepsy, and multiple sclerosis), malignancy, renal disease (e.g., chronic kidney disease, lupus nephritis, and nephrotic syndrome), and pulmonary disease (e.g., chronic obstructive pulmonary disease, restrictive lung disease, and pneumonia). Only comorbid diseases diagnosed prior to the diagnosis of BP were included in the present study. This study was approved by the Chonnam National University Hospital Institutional Review Board (IRB no. CNUH-2017-252).

Statistical analysis

The primary aim of this study was to investigate the survival of patients with BP during the 5 years following their diagnosis. Mortality rates at 1 year, 2 years, and 5 years following the diagnosis of BP were calculated using the Kaplan-Meier product limit estimator. To evaluate whether there was significant difference in the 5-year mortality rate among patients with BP based on baseline characteristics and morbidities, the Cox proportional hazard model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI). The ratio of the observed deaths of our group to expected deaths from 2007 to 2015, or the SMR, was calculated for patients in 10-year age intervals. The expected age- and sex-adjusted mortality in a general Korean population was calculated using the mortality rate for year at initial diagnosis from life tables of the Korean Statistical Information Service. An SMR of 1 means that observed and expected age- and sex-adjusted mortality rates are equal.

The secondary aim was to investigate the comorbidity profiles of patients with BP. Hypertension, diabetes, chronic kidney disease, stroke, Parkinson's disease, and dementia were included. We compared between the prevalence of comorbidities of patients with BP and that of a general population in Korea. Conditional logistic regressions were performed to calculate the odds ratio (OR) and 95% CI to estimate the associations between individual diseases and BP. A p-value <0.05 was considered statistically significant. Tables from the Korean Health Insurance Review and Assessment Service in 2012 were used to determine the expected prevalence in a general population of Koreans. IMB SPSS ver. 21.0 (IBM Co., Armonk, NY, USA) and R 3.2.2 were used for statistical analysis.

Go to :

RESULTS

Demographic data

In total, 103 patients with BP were included in this study. Of these patients, 53 (51.5%) were male and 50 (48.5%) were female (Table 1). The mean age±standard deviation (SD) at which BP was diagnosed was 74.4±10.6 years, and the median age was 76 years (range, 41~96 years). The majority of patients (89.3%) were aged ≥60 years. The mean duration of follow-up for those alive at the end of the analysis was 66.4 months, and for all patients, the mean duration of follow-up was 47.1 months.

Table 1

Demographic characteristics of patients with BP

Characteristic	Value
Total patients	103
Age at diagnosis (yr)	74.4±10.6
Age at diagnosis (yr)
40~49	3 (2.9)
50~59	8 (7.8)
60~69	15 (14.6)
70~79	45 (43.7)
≥80	32 (31.1)
Sex
Male	53 (51.5)
Female	50 (48.5)
Mean duration of follow-up (mo)	47.1±32.2

Values are presented as number only, mean±standard deviation, or number (%).

In this study population, systemic corticosteroids were the most frequently prescribed medications; in fact, all of the study participants received corticosteroids. Other therapeutic agents include dapsone, colchicine, mycophenolate mofetil, and azathioprine, among others.

Mortality and standardized mortality ratio

Of the 103 patients included in this study, 61 (59.22%) were still alive at the time of the final analysis. The 1-year, 2-year, and 5-year mortality rates for our BP cohort were 18.44% (95% CI, 10.62~25.63), 28.16% (95% CI, 18.88~36.30), and 42% (95% CI, 31.33~51.00), respectively. A survival curve of BP patients is shown in Fig. 1.

Fig. 1

Kaplan-Meier estimates of survival probability of patients with bullous pemphigoid after initial diagnosis. The solid blue line indicates the survival probability, while the dotted lines indicate the 95% confidence intervals.

The results of the SMR analysis are shown in Table 2. The SMR ranged from 0 to 2.35, depending on the age. The mortality of patients in our BP cohort was higher than the expected mortality of age- and sex-matched individuals in the general population for aged ≥70 years. The SMR was significantly elevated, particularly in patients aged 70~79 years.

Table 2

SMRs of observed deaths in patients with bullous pemphigoid versus expected deaths among the general Korean population

Age group (yr)	Patients (n)	Observed deaths (n)	Expected deaths (n)	SMR (95% CI)
<60	11	0	2.8	0
60~69	15	2	2.5	0.80 (0.13~2.64)
70~79	45	23	9.8	2.35 (1.52~3.47)
≥80	32	17	7.8	2.18 (1.31~3.42)
Total	103	42	22.9	1.83 (1.34~2.46)

SMR: standardized mortality ratio, CI: confidence interval.

Risk factors

Factors related to 5-year mortality were evaluated and shown in Table 3. Age at the time of diagnosis of over 70 was significantly associated with higher mortality (HR, 9.32; 95% CI, 2.25~38.60). Among the comorbidities, cardiac disease (HR, 2.50; 95% CI, 1.15~5.40) and renal disease (HR, 2.99; 95% CI, 1.38~6.48) were significantly associated with elevated mortality in the univariate analysis. However, age at the time of diagnosis and renal disease remained significantly associated with elevated mortality in the multivariate analysis. Patients with BP having hypertension, stroke, neurological disease, pulmonary disease, dementia and malignancies generally showed increased mortality; however, there was no significant difference in the mortality rate.

Table 3

Results of the univariate and multivariate analyses for 5-year mortality in patients with bullous pemphigoid

Variable	Patient (n, %)	Deaths (n, %)	Univariable HR (95% CI)	Univariable p-value	Multivariable HR (95% CI)	Multivariable p-value
Sex
Male	53 (51.5)	24 (45.3)
Female	50 (48.5)	18 (36.0)	1.52 (0.82~2.79)	0.184
Age at diagnosis (yr)
≥70	77 (74.8)	40 (51.9)	9.32 (2.25~38.60)	0.002	14.79 (3.26~67.23)	0.0004
<70	26 (25.2)	2 (7.7)
Comorbidities
Hypertension	50 (48.5)	22 (44.0)	1.23 (0.67~2.25)	0.505
Diabetes	33 (32.0)	13 (39.4)	0.99 (0.52~1.91)	0.978
Cardiac disease	11 (10.7)	8 (72.7)	2.50 (1.15~5.40)	0.020	1.70 (0.14~3.65)	0.675
Renal disease	11 (10.7)	8 (72.7)	2.99 (1.38~6.48)	0.050	7.73 (1.61~37.06)	0.011
Stroke	22 (21.4)	12 (54.5)	1.67 (0.86~3.27)	0.132
Neurologic disease	12 (11.7)	6 (50.0)	1.31 (0.55~3.12)	0.537
Pulmonary disease	7 (6.8)	5 (71.4)	2.31 (0.91~5.89)	0.080
Malignancy	12 (11.7)	6 (50.0)	1.49 (0.63~3.53)	0.370
Dementia	24 (23.3)	12 (50.0)	1.45 (0.74~2.83)	0.282

HR: hazard ratio, CI: confidence interval.

Comorbidity profiles

Comorbidities of patients with BP compared with general population are shown in Table 4. Our results showed that the presence of diabetes (OR, 1.64; 95% CI, 1.06~2.55), stroke (OR, 3.55; 95% CI, 2.09~6.03), Parkinson's disease (OR, 3.45; 95% CI, 1.49~7.98), and dementia (OR, 2.76; 95% CI, 1.67~4.56) were significantly associated with BP compared to the general population. Although hypertension was the most common comorbidity, it was not significant.

Table 4

Prevalence of comorbid diseases in patients with bullous pemphigoid compared with the general population

Disease	Patient (n)	Observed prevalence (%)	Expected prevalence (%)	OR (95% CI)	p-value
Hypertension	50	48.5	65.7	0.63 (0.42~0.95)	0.036
Diabetes	33	32.0	22.3	1.64 (1.06~2.55)	0.026
Chronic kidney disease	11	10.7	17.4	0.56 (0.30~1.08)	0.109
Stroke	22	21.4	7.1	3.55 (2.09~6.03)	<0.001
Parkinson's disease	6	5.8	1.8	3.45 (1.49~7.98)	0.0067
Dementia	24	23.3	9.9	2.76 (1.67~4.56)	0.0001

OR: odds ratio, CI: confidence interval.

Go to :

DISCUSSION

In this study of 103 Korean patients with BP, we observed 1-year, 2-year, and 5-year mortality rates of 18.44%, 28.16% and 42.00%, respectively; these results were lower or similar to those reported in European studies19 20 21 30. However, the mean age of the patients in our study was 74.4±10.6 (SD) years, which is approximately 5 years younger than that of previous European studies20 21 28. Considering the younger age, our results are consistent with those of the European studies. A recent study from Finland showed a 1-year mortality 16.7%, which is lower than our results30. Some US-based studies reported lower mortality rates than European studies, although a recent US-based cohort study demonstrated a higher mortality rate that was closer to those seen in our results and previous European data11 16. Recently, several studies regarding the mortality rates of patients with BP have been conducted in Asian countries. The mortality rates and SMR analyses of patients with BP from Asian studies are shown in Table 5 22 23 26 27. One study from China23 showed a slightly higher 1-year mortality rate compared to our study (23.4%), while another study from China reported lower 1-, 2-, and 5-year mortality rates at 12.9%, 20.1% and 33.5%, respectively22. Considering that the mean age of the patients from the latter Chinese study was 67 years, this disparity in mortality rate is justifiable. One Singaporean study reported a higher 1-year mortality rate (26.7%) than that of our study. The mean age of their study patients was slightly older (75.7 years) compared to ours (74.4 years)26. A recent retrospective study from Korea with a total of 168 BP patients reported 1-, 2-, and 5-year mortality rates of 19.46%, 29.13% and 58.03%, respectively27. These values are slightly higher than ours, despite the lower mean age of the study population (69.2 years) compared to ours27.

Table 5

Mortality rates and standardized mortality ratios (SMRs) for bullous pemphigoid patients from Asian studies

Author	Country	Mean age (yr)	1-year mortality (%)	2-year mortality (%)	3-year mortality (%)	5-year mortality (%)	SMR
Li et al.22 (2013)	China	67	12.9	20.1		33.5	3.08~6.14
Zhang et al.23 (2013)	China	71	23.4
Cai et al.26 (2014)	Singapore	75.7	26.7	38.4	45.7		2.74
Lee and Kim27 (2014)	Korea	69.2	19.46	29.13		58.03	2.43~9.56
Our study	Korea	74.4	18.44	28.16		42.00	1.83

We compared the mortality rate of patients with BP with those of an age- and sex-matched general population. From our results, we found that patients with BP had increased rates of mortality compared to the general population. In those aged ≥70 years, the mortality rate of BP patients was higher than the expected rate for the general population, particularly in patients who were 70 to 79 years old. Several cohort studies from Europe have reported that patients with BP have increased mortality compared with age-matched general populations19 21 28. In addition, recent Asian studies reported significantly higher SMR among patients with BP compared to the general population22 26 27. Our data support the results of these reports, in which BP is significantly associated with increased mortality.

BP was associated with a number of antibody-mediated autoimmune, infectious, cardiovascular, neurological, and psychiatric disorders. Our results showed that the prevalence of diabetes, stroke, Parkinson's disease, and dementia were significantly associated with BP compared to that of the general population. The increased prevalence of diabetes is likely to be related to prior treatment with corticosteroids; however, the exact reason for this association is unclear. Studies have shown that patients with BP are most very likely to have neurological diseases as stroke, dementia, and Parkinson's disease35 36 37 38 39. A recent cohort study from USA showed that patients with BP had numerous neuropsychiatric disorders, including dementia and Parkinson's disease31. The pathomechanism underlying the association between neurological diseases and BP is not fully understood; however, autoimmunity against BP antigens in the brain that cross-react with the skin have been proposed as a possible triggering factor26. Our results are consistent with recent studies and support the hypothesis that a neuronal isoform of BPAG1 may secondarily trigger an autoimmune response against the epithelial isoform of BPAG134 35 36.

We examined the risk factors associated with the 5-year mortality of patients with BP. Recent studies have evaluated the risk factors related to 1-year or 3-year mortality. In this study, we believed it was necessary to evaluate both the 5-year mortality rate and risk factors as the mortality rate of patients with BP at 5-year follow-up were significantly higher than those at 1-year and 3-year follow-up. Old age at the time of diagnosis (especially over 70 years) was found to be associated with an increased 5-year mortality rate, consistent with previous reports. Previous European reports have shown that an age of over 80 years was a poor prognostic factor for patients with BP. However, recent Korean reports demonstrated that an age of over 70 years at diagnosis is a risk factor for poor prognosis, in keeping with our results9 14 19 20 27 28.

Cardiac and renal diseases were also associated with an increased mortality rate in our study. There were 14 patients with cardiac disease and 14 patients with renal disease among our patients with BP; 7 patients belonged to both disease groups. While the pathomechanism is unclear, diuretics, which are commonly used in both cardiac and renal diseases, have been found to be a risk factor for aggravation of BP in the elderly36 40 41. However, it is unclear whether the use of diuretics is associated with a higher mortality rate. A recent study from Singapore showed that cardiac disease, particularly heart failure, significantly increased the mortality of patients with BP26. Further investigation is required to identify the association between these diseases and increased mortality.

Interestingly, dementia, diabetes and stroke, which many studies have reported to be poor prognostic factors, did not demonstrate increased risk of 5-year mortality in our study16 19 20 22 23 27. In a recent Korean study, a history of diabetes also showed an increased risk of 1-year mortality, and stroke was shown to be a poor prognostic factor for overall survival27. Neurological disease, which prior studies demonstrated as a poor prognostic factor16 19 20 35, was not associated with increased 5-year mortality. Some of these studies have classified dementia and stroke as neurological diseases but we evaluated each disease individually. In other Korean study, a history of dementia and neurological disease didn't showed an increased risk of 1-year and overall mortality27, which is consistent with our result. There are several limitations of this study. First, we retrospectively evaluated patients with BP by using medical records and direct telephone calls. Second, our study was a single-center study, consisted of a relatively small sample size (n=103), and excluded patients who were lost to follow-up; therefore, there might be selection bias. Third, we failed to obtain data regarding the exact cause of death.

In conclusion, the mortality rate of patients with BP is higher than that of the general population. Korean patients with BP are more likely to have dementia, Parkinson's disease, diabetes mellitus, and stroke. Risk factors for increased mortality include old age at the time of diagnosis, medical comorbidities, especially cardiac and renal diseases. Dermatologists should therefore be extra cautious when they encounter and care for patients with BP with these underlying risk factors.

Go to :

Notes

CONFLICTS OF INTEREST: The authors have nothing to disclose.

Go to :

References

1. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013; 381:320–332. PMID: 23237497.

2. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol. 2007; 23:257–288. PMID: 18159905.

3. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977; 113:1043–1046. PMID: 329769.

4. Bernard P, Enginger V, Venot J, Bedane C, Bonnetblanc JM. Survival prognosis in pemphigoid. A cohort analysis of 78 patients. Ann Dermatol Venereol. 1995; 122:751–757. PMID: 8729818.

5. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995; 131:48–52. PMID: 7826096.

6. Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997; 136:694–698. PMID: 9205501.

7. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998; 134:465–469. PMID: 9554299.

8. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002; 346:321–327. PMID: 11821508.

9. Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002; 138:903–908. PMID: 12071817.

10. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004; 122:1091–1095. PMID: 15140208.

11. Bystryn JC, Rudolph JL. Why is the mortality of bullous pemphigoid greater in Europe than in the US? J Invest Dermatol. 2005; 124:xx–xxi. PMID: 15737186.

12. Garcia-Doval I, Conde Taboada A, Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol. 2005; 124:666–667. PMID: 15737212.

13. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol. 2005; 153:424–427. PMID: 16086760.

14. Joly P, Benichou J, Lok C, Hellot MF, Saiag P, Tancrede-Bohin E, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005; 141:691–698. PMID: 15967914.

15. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ. 2008; 337:a180. PMID: 18614511.

16. Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008; 59:582–588. PMID: 18707800.

17. Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009; 161:861–868. PMID: 19566661.

18. Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol. 2009; 145:1005–1008. PMID: 19770439.

19. Cortés B, Marazza G, Naldi L, Combescure C, Borradori L. Autoimmune Bullous Disease Swiss Study Group. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol. 2011; 165:368–374. PMID: 21574978.

20. Cortés B, Khelifa E, Clivaz L, Cazzaniga S, Saurat JH, Naldi L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology. 2012; 225:320–325. PMID: 23257934.

21. Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012; 132:1998–2004. PMID: 22418872.

22. Li J, Zuo YG, Zheng HY. Mortality of bullous pemphigoid in China. JAMA Dermatol. 2013; 149:106–108. PMID: 23324774.

23. Zhang LM, Wu J, Xiao T, Jin GY, Li JH, Geng L, et al. Treatment and mortality rate of bullous pemphigoid in China: a hospital-based study. Eur J Dermatol. 2013; 23:94–98. PMID: 23419247.

24. Bernard P. Mortality of bullous pemphigoid in Asia: the same as in Europe? Br J Dermatol. 2014; 170:1216–1217.

25. Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014; 71:92–99. PMID: 24704091.

26. Cai SC, Allen JC, Lim YL, Chua SH, Tan SH, Tang MB. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. Br J Dermatol. 2014; 170:1319–1326. PMID: 24372558.

27. Lee JH, Kim SC. Mortality of patients with bullous pemphigoid in Korea. J Am Acad Dermatol. 2014; 71:676–683. PMID: 24930586.

28. Gual A, Mascaró JM Jr, Rojas-Farreras S, Guilabert A, Julià M, Iranzo P. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. J Eur Acad Dermatol Venereol. 2014; 28:500–506. PMID: 23279207.

29. Serwin AB, Musialkowska E, Piascik M. Incidence and mortality of bullous pemphigoid in north-east Poland (Podlaskie Province), 1999-2012: a retrospective bicentric cohort study. Int J Dermatol. 2014; 53:e432–e437. PMID: 25041554.

30. Försti AK, Jokelainen J, Timonen M, Tasanen K. Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol. 2016; 96:758–761. PMID: 26806363.

31. Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. 2017; 176:87–99. PMID: 27343837.

32. Laffitte E, Burkhard PR, Fontao L, Jaunin F, Saurat JH, Chofflon M, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol. 2005; 152:537–540. PMID: 15787824.

33. Groves RW, Liu L, Dopping-Hepenstal PJ, Markus HS, Lovell PA, Ozoemena L, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol. 2010; 130:1551–1557. PMID: 20164846.

34. Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011; 165:593–599. PMID: 21517800.

35. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011; 131:631–636. PMID: 21085189.

36. Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011; 131:637–643. PMID: 20944650.

37. Cordel N, Chosidow O, Hellot MF, Delaporte E, Lok C, Vaillant L, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007; 215:187–191. PMID: 17823513.

38. Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010; 146:1251–1254. PMID: 21079062.

39. Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases-a case-control study. Eur J Dermatol. 2010; 20:96–101. PMID: 19797038.

40. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996; 132:272–276. PMID: 8607630.

41. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013; 149:58–62. PMID: 23324757.

Go to :

TOOLS

Similar articles